SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Google

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
How heart failure risk rises after surgery
Wed June 29th - The development of atrial fibrillation following surgery is an important risk factor for heart failure, researchers report today. More
Brain surgery benefits intracranial pressure
Wed June 29th - Craniectomy for intracranial hypertension offers significant benefit, according to new guidance, triggered by British research. More
RECENT COMMENTS
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
OUR CLIENTS
THIS WEEK'S STORIES
ENGLEMED HEALTH NEWS

Flu jab risk for cancer patients

Wednesday April 26th, 2017

The annual flu jab may pose a specific risk to lung cancer patients who are being treated with drugs known as PD-1/PD-L1 checkpoint inhibitors, a European conference has heard.

This finding comes from a study of 23 patients with non-small-cell lung cancer, renal cell carcinoma, or melanoma. Just over half had been given at least two rounds of chemotherapy and all were currently taking PD-1/PD-L1 inhibitors nivolumab or pembrolizumab.

PD-1 is known as a checkpoint protein on T cells. It normally prevents T cells from attacking healthy cells by attaching to PD-L1, but some cancer cells have large amounts of PD-L1, which protects them from the immune system. PD-1/PD-L1 inhibitors overcome this defence.

The participants received a trivalent flu vaccination and their outcomes were compared against ten similar but cancer-free participants.

This showed an unusual high frequency of immune-related adverse events (52%), including six patients who experienced severe grade 3 or 4 immune-related adverse events.

Lead researcher Dr Sacha Rothschild of University Hospital Basel, Switzerland, will present the results on 6 May at the European Lung Cancer Conference 2017 in Geneva, Switzerland.

He said: "Use of immune checkpoint inhibitors is now standard clinical practice for many oncology patients, and these same patients - particularly those with lung cancer - also face increased risk for complications from influenza.

"Although routine influenza vaccination has long been recommended for cancer patients, there are concerns that it might trigger an exaggerated immune response in this subgroup receiving checkpoint inhibitors."

Though he added that these results, suggesting a possible contraindication, must be confirmed in a larger study.

Immune response and adverse events to influenza vaccine in cancer patients undergoing PD-1 blockade, Abstract 112P_PR, presented on 6 May at the European Lung Cancer Conference 2017, held from 5-8 May 2017, in Geneva, Switzerland.

Tags: Cancer | Europe | Flu & Viruses | Pharmaceuticals

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES